LifeMD (LFMD) AI Stock Analysis

• Market Cap: $184.84M
• Dividend Yield: N/A
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.56
• Revenue Growth: 30.71%
• EPS Growth: 73.43%
• Country: US
• Employees: 304
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.10
• Shares Outstanding: 48,135,883
• 10 Day Avg. Volume: 2,356,590
• 30 Day Avg. Volume: 1,332,713
• PEG Ratio: 0.44
• Price to Book (P/B): -37.17
• Price to Sales (P/S): 0.96
• P/FCF Ratio: 34.12
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: 1.18
• Enterprise Value/Gross Profit: 1.36
• Enterprise Value/Ebitda: 28.27
• 1Y Price Target: $9.67
• Price Target Upside: 151.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.21
• Revenue Forecast (FY): $237.22M

• Rating: 47 Neutral
• Price Target: $4.50 ▲(17.19% Upside)

LifeMD's overall score is driven by financial instability and bearish technical indicators. While the earnings call highlighted growth potential and strategic partnerships, the company's high leverage and negative profitability weigh heavily on its outlook.

Positive Factors

Revenue Growth

Consistent revenue growth in telehealth indicates strong market demand and effective business model execution, supporting long-term expansion.

Strategic Partnerships

Partnerships with major pharmaceutical companies enhance product offerings and competitive positioning, driving sustainable growth.

Cash Flow Health

Strong cash flow growth indicates robust financial health, enabling reinvestment in growth initiatives and improving financial stability.

Negative Factors

High Debt Levels

Excessive leverage can strain financial flexibility and increase risk, potentially impacting long-term operational stability.

Profitability Challenges

Ongoing profitability issues highlight challenges in cost management and achieving sustainable margins, affecting long-term viability.

Weight Management Competition

Competitive pressures in key segments can hinder market share growth and profitability, impacting strategic objectives.

LifeMD Business Overview & Revenue Model

Company Description

LifeMD (LFMD) is a telehealth company focused on providing patients with convenient access to a range of healthcare services, including telemedicine consultations, prescription medications, and wellness products. The company operates in the digital health sector, leveraging technology to connect patients with licensed medical professionals for various health needs, such as chronic disease management, weight loss, and dermatological treatments. LifeMD's core offerings include virtual consultations, subscription-based treatment plans, and a comprehensive online pharmacy service that allows patients to receive medications directly to their homes.

How the Company Makes Money

LifeMD generates revenue through several key streams, primarily by charging for telehealth consultations and subscription services. Patients can pay for one-time virtual visits or opt for monthly subscription plans that provide ongoing access to healthcare professionals and personalized treatment plans. Additionally, the company earns money from the sale of prescription medications through its online pharmacy, which allows for direct shipping to patients. Significant partnerships with pharmaceutical companies and health-related brands also contribute to LifeMD's earnings, as they often collaborate on marketing initiatives and product offerings, enhancing the company's service portfolio and revenue potential.

LifeMD Financial Statement Overview

Summary

LifeMD shows potential with revenue growth and strong gross profit margins. However, high debt levels, negative net profit margins, and financial instability due to significant leverage are concerning.

Income Statement

LifeMD shows a positive revenue growth trend with a 3.01% increase in TTM, indicating potential market expansion. However, the company struggles with profitability, as evidenced by a negative net profit margin of -2.25% and a low EBIT margin of 1.11%. The gross profit margin is strong at 91.64%, suggesting efficient cost management, but the net losses highlight ongoing challenges in achieving sustainable profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 4.96, indicating significant leverage and potential financial risk. The return on equity is positive at 2.60%, showing some return on shareholder investment, but the low equity ratio suggests a weak capital structure. Overall, the balance sheet reflects financial instability and high reliance on debt financing.

Cash Flow

LifeMD's cash flow statement shows a positive free cash flow growth rate of 27.97%, indicating improved cash generation capabilities. The operating cash flow to net income ratio of 0.23 suggests moderate cash flow efficiency. However, the free cash flow to net income ratio of 1.29 indicates that free cash flow exceeds net income, which is a positive sign of cash flow health despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	252.34M	212.45M	152.55M	119.03M	92.88M	37.29M
Gross Profit	219.43M	188.39M	133.65M	100.37M	74.88M	28.43M
EBITDA	10.55M	-6.65M	-7.89M	-38.60M	-53.95M	-57.48M
Net Income	-4.60M	-18.88M	-20.60M	-45.54M	-60.90M	-58.65M
Balance Sheet
Total Assets	65.98M	72.46M	58.48M	25.67M	49.92M	13.40M
Cash, Cash Equivalents and Short-Term Investments	23.79M	35.00M	33.15M	3.96M	41.33M	9.18M
Total Debt	6.53M	25.10M	18.93M	4.13M	1.85M	1.06M
Total Liabilities	62.62M	76.51M	52.91M	32.97M	24.10M	14.22M
Stockholders Equity	1.31M	-5.49M	3.51M	-6.83M	26.85M	1.35M
Cash Flow
Free Cash Flow	16.98M	5.98M	86.95K	-35.83M	-36.49M	-12.53M
Operating Cash Flow	13.13M	17.51M	8.82M	-22.94M	-33.09M	-12.13M
Investing Cash Flow	-12.88M	-11.54M	-8.73M	-13.91M	-3.40M	-798.14K
Financing Cash Flow	-14.05M	-4.12M	29.10M	-528.20K	68.64M	21.00M

LifeMD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFMD, the sentiment is Negative. The current price of 3.84 is below the 20-day moving average (MA) of 4.78, below the 50-day MA of 5.76, and below the 200-day MA of 7.68, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 24.16 is Positive, neither overbought nor oversold. The STOCH value of 29.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFMD.

LifeMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFMD	47 Neutral	$184.84M	―	―	―	30.71%	73.43%
PETS	43 Neutral	$37.20M	―	―	―	-19.25%	14.47%
YI	37 Underperform	$38.38M	-3.73	―	―	-2.17%	77.71%

LifeMD Corporate Events

LifeMD, Inc. Reports Strong Q3 2025 Results

LifeMD, Inc. is a prominent provider of virtual primary care services, offering telemedicine and pharmacy solutions across a wide range of health conditions. The company is known for its vertically integrated digital care platform and extensive reach across the United States.

LifeMD Delays Quarterly Report Filing

LifeMD Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the need for additional time to finalize adjustments correcting errors related to the over-recognition of revenue, amounting to approximately $4.6 million. These adjustments will not affect the company’s cash flow or cash position. The company expects to file the report within five calendar days following the original due date. While no significant changes in financial results are anticipated, LifeMD is evaluating the potential impact on its internal control over financial reporting. The notification was signed by Marc Benathen, the Chief Financial Officer, as the company continues its compliance efforts.

The most recent analyst rating on (LFMD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Reschedules Q3 Earnings Call Amid Revenue Adjustments

On November 5, 2025, LifeMD announced the rescheduling of its third quarter 2025 earnings release and conference call to November 17, 2025, due to corrections identified in revenue recognition related to past data system migrations. The adjustments, impacting approximately $4.6 million or 1.4% of cumulative revenue, will not materially affect reported revenue results or the company’s cash flow and position. This decision reflects LifeMD’s commitment to accurate financial reporting and transparency, ensuring stakeholders are informed of the necessary adjustments without significant operational impact.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.

LifeMD Divests WorkSimpli Stake to Focus on Healthcare

On November 4, 2025, LifeMD, Inc. completed the sale of its majority interest in WorkSimpli Software LLC, valuing the company at approximately $65 million. This strategic divestiture allows LifeMD to focus on expanding its virtual care and pharmacy services, reinforcing its position as a pure-play healthcare company. The transaction, which involved a cash payment of $22 million at closing and potential additional earnings based on performance targets, is expected to strengthen LifeMD’s balance sheet and accelerate growth in its core business areas. The move is seen as a pivotal step in LifeMD’s transformation, enabling the company to concentrate on its primary healthcare offerings and expand into new clinical verticals.

The most recent analyst rating on (LFMD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on LifeMD stock, see the LFMD Stock Forecast page.